Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Cholangiocarcinoma
Cholangiocarcinoma
The Use of Molecular Biomarker Testing in Patients with CCA
By
Vaibhav Sahai, MBBS, MS
;
Milind M. Javle, MD
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Vaibhav Sahai discusses different approaches to molecular biomarker testing, including when to order the tests in the course of the disease, use of institutional and commercial testing facilities, and what platforms exist for testing.
Read Article
Current Approaches to Treatment of Advanced CCA
By
Angela Lamarca, MD, PhD, MSc
;
Milind M. Javle, MD
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Angela Lamarca discusses approaches to first- and second-line therapy for patients with advanced CCA.
Read Article
Surgery for Cholangiocarcinoma: Before and After
Cholangiocarcinoma
December 2019 Highlights from the First Annual Cholangiocarcinoma Summit
At the First Annual Cholangiocarcinoma Summit, presenters discussed recent advances in the management of patients with cholangiocarcinoma (CCA), including new surgical approaches, the expanding role of liver-directed therapies, radiation, and transplantation, and more effective sequencing of neoadjuvant and adjuvant therapies.
Read Article
Updates on the Understanding of Cholangiocarcinoma
Cholangiocarcinoma
December 2019 Highlights from the First Annual Cholangiocarcinoma Summit
On October 17 and 18, 2019, a group of international experts convened in Phoenix, AZ, for the First Annual Cholangiocarcinoma Summit. The goal of the meeting was to discuss the latest clinical data on the disease, as well as the implications of these findings for providers and patients.
Read Article
Medical Management of Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma
December 2019 Highlights from the First Annual Cholangiocarcinoma Summit
According to several presenters at the First Annual Cholangiocarcinoma Summit, advances in systemic treatment for cholangiocarcinoma (CCA) are emerging, including cytotoxic chemotherapy.
Read Article
Pemigatinib Effective in Patients with Cholangiocarcinoma and FGFR2 Fusion or Rearrangement
By
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Data from the single-arm, open-label phase 2 clinical trial FIGHT-202, which was presented at the ESMO Congress 2019, revealed that investigational pemigatinib induced a response in 35.5% of the 107 patients with
FGFR2
fusions or rearrangements (cohort A), with a median duration of response of 7.5 months.
Read Article
Practice-Changing Results: Ivosidenib First Targeted Therapy to Show Benefits in Patients with Cholangiocarcinoma and IDH1 Mutation
By
Wayne Kuznar
Cholangiocarcinoma
December 2019, Vol 10, No 6
Barcelona, Spain—Ivosidenib (Tibsovo), an oral therapy that targets isocitrate dehydrogenase-1 (
IDH1
) mutation, significantly improved progression-free survival (PFS) in patients with advanced cholangiocarcinoma (CCA) and an
IDH1
mutation, in a phase 3 clinical trial reported lead investigator Ghassan K. Abou-Alfa, MD, Medical Oncologist, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the ESMO Congress 2019.
Read Article
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
By
Wayne Kuznar
Cholangiocarcinoma
October 2019, Vol 10, No 5
Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumor-specific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient. The molecular profile of CCA can be done through the use of circulating tumor (ct) DNA sequencing, which may help to target specific mutations and improve treatment selection for this rare type of cancer.
Read Article
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
By
Wayne Kuznar
Cholangiocarcinoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—A greater understanding of the biology of cholangiocarcinoma, including differences between intrahepatic versus extrahepatic cholangiocarcinoma, is driving the development of new therapeutic options that have shown promising results in advanced stages of this difficult-to-treat cancer.
Read Article
Page 5 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma